Researchers found no association between the use of DPP-4 inhibitors, GLP-1 receptor agonists, or SGLT2 inhibitors and the risk for fracture in patients with type 2 diabetes.
The approval of Victoza in this patient population was based on data from the ELLIPSE trial which included 134 children and adolescents.
To learn more about weight-neutral diabetes care, Endocrinology Advisor checked in with experts in the field to discuss existing research and takeaways for clinicians.
Can a weight-neutral approach improve care for patients with diabetes?
Fewer new type 2 diabetes (T2D) cases are seen in adults who eat more plant-based foods, and intake of vitamins B2 and B6 is also associated with a reduced risk for T2D.
Patients with midlife type 2 diabetes have a significantly increased risk for cerebral infarction and occlusion of cerebral arteries later in life.
Researchers examined the association between cholesterol metabolism and sciatic nerve alterations in T2D.
Findings showed a legacy effect of participation in the behavioral weight loss intervention that led to reduced reward-related activity and enhanced attention and visual processing in response to high-calorie food cues.
Adhering to a Mediterranean diet and effectively managing type 2 diabetes may support optimal cognitive function.
Results showed non-inferiority for linagliptin vs glimepiride in meeting its primary endpoint of time to first occurrence of CV death, non-fatal myocardial infarction or non-fatal stroke.
